Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087835 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
A Phase 3 study of Chronic Kidney Disease With High Proteinuria, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,835
- Enrollment target
- 20
- Study locations
NCT06087835 is a Phase 3 study of Chronic Kidney Disease With High Proteinuria that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,835 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT06087835, a Phase 3 study of Chronic Kidney Disease With High Proteinuria, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,835 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
Conditions Studied
Interventions
- DRUG Dapagliflozin
- DRUG Zibotentan/Dapagliflozin
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Huntington Park
- Research Site - Los Alamitos
- Research Site - Los Angeles
- Research Site - Northridge
- Research Site - Oxnard
- Research Site - San Carlos
- Research Site - San Dimas
- Research Site - Tarzana
- Research Site - Victorville
Florida
- Research Site - Boynton Beach
- Research Site - Hialeah
- Research Site - Hollywood
- Research Site - Jacksonville
- Research Site - Jensen Beach
- Research Site - Miami
Colorado
- Research Site - Arvada
- Research Site - Denver
Alabama
- Research Site - Huntsville
Arizona
- Research Site - Sun City West
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,835 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2027-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06087835
The ClinicalTrials.gov registry entry for NCT06087835 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,835 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Disease With High Proteinuria appearing as the primary indexed condition, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT06087835 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06087835 about?
NCT06087835 is a clinical study titled "Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)". This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
What is the current status of trial NCT06087835?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,835 participants. The study started on 2023-11-07. Estimated completion is 2027-01-22.
What conditions does trial NCT06087835 study?
This clinical trial studies the following conditions: Chronic Kidney Disease With High Proteinuria.
What interventions are being tested in trial NCT06087835?
The interventions under investigation include: Dapagliflozin (DRUG), Zibotentan/Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT06087835?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06087835 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.